<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>DURICEF- cefadroxilÂ powder, for suspensionÂ </strong><br><strong>DURICEF- cefadroxilÂ tabletÂ </strong><br><strong>DURICEF- cefadroxilÂ capsuleÂ </strong><br>Warner Chilcott, Inc.<br></p></div>
<h1>Duricef<span class="Sup">Â®</span><br>(cefadroxil monohydrate, USP)</h1>
<div class="Contents">
<div class="Section">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_44EDD372-CBD8-467C-8836-91BDA534536A"></a><a name="section-2"></a><p></p>
<p class="First">To reduce the development of drug-resistant bacteria and maintain the effectiveness of DURICEF<span class="Sup">Â®</span> and other antibacterial drugs, DURICEF should be used only to treat or prevent <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> that are proven or strongly suspected to be caused by bacteria.</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="i4i_description_ID_0F7BAFDB-E9D5-4195-9A6E-3097494CC6E8"></a><a name="section-3"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">DURICEF is a semisynthetic cephalosporin antibiotic intended for oral administration. It is a white to yellowish-white crystalline powder. It is soluble in water and it is acid-stable. It is chemically designated as 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 7-[[amino(4-hydroxyphenyl)acetyl]amino]-3-methyl-8-oxo-, monohydrate[6R-[6Î±,7Î²(R*)]]-. It has the formula C<span class="Sub">16</span>H<span class="Sub">17</span>N<span class="Sub">3</span>O<span class="Sub">5</span>S â€¢ H<span class="Sub">2</span>O and the molecular weight of 381.40. It has the following structural formula:</p>
<div class="Figure"><img alt="Image from Drug Label Content" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=4AD759F3-72DD-412E-9500-055335CDA6CF&amp;name=duricef-01.jpg"></div>
<p>DURICEF film-coated tablets, 1 g, contain the following inactive ingredients: microcrystalline cellulose, hydroxypropyl methylcellulose, magnesium stearate, polyethylene glycol, polysorbate 80, simethicone emulsion, and titanium dioxide.</p>
<p>DURICEF for Oral Suspension contains the following inactive ingredients: FD&amp;C Yellow No. 6, flavors (natural and artificial), polysorbate 80, sodium benzoate, sucrose, and xanthan gum.</p>
<p>DURICEF capsules contain the following inactive ingredients: D&amp;C Red No. 28, FD&amp;C Blue No. 1, FD&amp;C Red No. 40, gelatin, magnesium stearate, and titanium dioxide.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="i4i_clinical_pharmacology_ID_91367931-B5CE-42C3-9F25-821DB48C7F58"></a><a name="section-4"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<p class="First">DURICEF is rapidly absorbed after oral administration. Following single doses of 500 mg and 1000 mg, average peak serum concentrations were approximately 16 and 28 Î¼g/mL, respectively. Measurable levels were present 12 hours after administration. Over 90% of the drug is excreted unchanged in the urine within 24 hours. Peak urine concentrations are approximately 1800 Î¼g/mL during the period following a single 500 mg oral dose. Increases in dosage generally produce a proportionate increase in DURICEF (cefadroxil monohydrate, USP) urinary concentration. The urine antibiotic concentration, following a 1 g dose, was maintained well above the MIC of susceptible urinary pathogens for 20 to 22 hours.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_A7AF600E-A841-4AF0-821A-824ECBB09A54"></a><a name="section-4.1"></a><p></p>
<h2>Microbiology</h2>
<p class="First"><span class="Italics">In vitro</span> tests demonstrate that the cephalosporins are bactericidal because of their inhibition of cell-wall synthesis. Cefadroxil has been shown to be active against the following organisms both <span class="Italics">in vitro</span> and in clinical <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> (see <span class="Bold"><span class="Emphasis"><a href="#i4i_indications_ID_AA9120E4-9712-41CC-AA86-5260FF7F1BBD">INDICATIONS AND USAGE</a></span></span>):</p>
<p><span class="Italics">Beta-hemolytic streptococci</span></p>
<p><span class="Italics">Staphylococci</span>, including penicillinase-producing <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span></p>
<p><span class="Italics">Streptococcus (Diplococcus) pneumoniae</span></p>
<p><span class="Italics">Escherichia coli</span></p>
<p><span class="Italics">Proteus mirabilis</span></p>
<p><span class="Italics">Klebsiella </span>species</p>
<p><span class="Italics">Moraxella (Branhamella) catarrhalis</span></p>
<p><span class="Bold"><span class="Emphasis">Note:</span></span> Most <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of <span class="Italics">Enterococcus faecalis</span> (formerly <span class="Italics">Streptococcus faecalis</span>) and <span class="Italics">Enterococcus faecium</span> (formerly <span class="Italics">Streptococcus faecium</span>) are resistant to DURICEF. It is not active against most <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of <span class="Italics">Enterobacter</span> species, <span class="Italics">Morganella morganii</span> (formerly <span class="Italics">Proteus morganii</span>), and <span class="Italics">P. vulgaris</span>. It has no activity against <span class="Italics">Pseudomonas</span> species and <span class="Italics">Acinetobacter calcoaceticus</span> (formerly <span class="Italics">Mima</span> and <span class="Italics">Herellea</span> species).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_60B61169-2E6E-4498-93F7-F639225800A4"></a><a name="section-4.2"></a><p></p>
<h2>Susceptibility tests: Diffusion techniques</h2>
<p class="First">The use of antibiotic disk susceptibility test methods which measure zone diameter give an accurate estimation of antibiotic susceptibility. One such standard procedure<span class="Sup">1</span> which has been recommended for use with disks to test susceptibility of organisms to cefadroxil uses the cephalosporin class (cephalothin) disk. Interpretation involves the correlation of the diameters obtained in the disk test with the <span class="product-label-link" type="condition" conceptid="4190299" conceptname="Broth microdilution susceptibility test">minimum inhibitory concentration</span> (MIC) for cefadroxil.</p>
<p>Reports from the laboratory giving results of the standard single-disk susceptibility test with a 30 Î¼g cephalothin disk should be interpreted according to the following criteria:</p>
<a name="ID_E1B63387-4E38-4213-9C37-F3F5CACE8034"></a><table border="none" frame="void" width="401">
<col width="46.633%">
<col width="53.367%">
<thead><tr class="First Last">
<td align="center" valign="middle"><span class="Bold"><span class="Emphasis">Zone diameter (mm)</span></span></td>
<td align="center" valign="middle"><span class="Bold"><span class="Emphasis">Interpretation</span></span></td>
</tr></thead>
<tbody>
<tr class="First">
<td align="center" valign="middle">â‰¥ 18</td>
<td align="center" valign="middle">(S) Susceptible</td>
</tr>
<tr>
<td align="center" valign="middle">15â€“17</td>
<td align="center" valign="middle">(I) Intermediate</td>
</tr>
<tr class="Last">
<td align="center" valign="middle">â‰¤ 14</td>
<td align="center" valign="middle">(R) Resistant</td>
</tr>
</tbody>
</table>
<p>Â </p>
<p>A report of â€œSusceptibleâ€? indicates that the pathogen is likely to be inhibited by generally achievable blood levels. A report of â€œintermediate susceptibilityâ€? suggests that the organism would be susceptible if high dosage is used or if the <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> is confined to tissue and fluids (e.g., urine) in which high antibiotic levels are attained. A report of â€œResistantâ€™â€™ indicates that achievable concentrations of the antibiotic are unlikely to be inhibitory and other therapy should be selected.</p>
<p>Standardized procedures require the use of laboratory control organisms. The 30 Î¼g cephalothin disk should give the following zone diameters:</p>
<a name="ID_05638499-0EC5-4B57-879F-EC7DE96F6CEB"></a><table border="none" frame="void" width="519.0360000000001">
<col width="68.796%">
<col width="31.204%">
<thead><tr class="First Last">
<td align="center" valign="top"><span class="Bold"><span class="Emphasis">Organism</span></span></td>
<td align="center" valign="top"><span class="Bold"><span class="Emphasis">Zone Diameter (mm)</span></span></td>
</tr></thead>
<tbody>
<tr class="First">
<td align="left" valign="top">
<span class="Italics">Staphylococcus aureus</span> ATCC 25923</td>
<td align="center" valign="top">29â€“37</td>
</tr>
<tr class="Last">
<td align="left" valign="top">
<span class="Italics">Escherichia coli</span> ATCC 25922</td>
<td align="center" valign="top">17â€“22</td>
</tr>
</tbody>
</table>
<p>Â </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_F7A11E06-E25F-45E6-A436-FAF034CD9BAA"></a><a name="section-4.3"></a><p></p>
<h2>Dilution Techniques</h2>
<p class="First">When using the NCCLS agar dilution or broth dilution (including microdilution) method<span class="Sup">2</span> or equivalent, a bacterial isolate may be considered susceptible if the MIC (<span class="product-label-link" type="condition" conceptid="4190299" conceptname="Broth microdilution susceptibility test">minimum inhibitory concentration</span>) value for cephalothin is 8 Î¼g/mL or less. Organisms are considered resistant if the MIC is 32 Î¼g/mL or greater. Organisms with an MIC value of less than 32 Î¼g/mL but greater than 8 Î¼g/mL are intermediate.</p>
<p>As with standard diffusion methods, dilution procedures require the use of laboratory control organisms. Standard cephalothin powder should give MIC values in the range of 0.12 Î¼g/mL and 0.5 Î¼g/mL for <span class="Italics">Staphylococcus aureus</span> ATCC 29213. For <span class="Italics">Escherichia coli</span> ATCC 25922, the MIC range should be between 4.0 Î¼g/mL and 16.0 Î¼g/mL. For <span class="Italics">Streptococcus faecalis</span> ATCC 29212, the MIC range should be between 8.0 and 32.0 Î¼g/mL.</p>
</div>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="i4i_indications_ID_AA9120E4-9712-41CC-AA86-5260FF7F1BBD"></a><a name="section-5"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First">DURICEF is indicated for the treatment of patients with <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> caused by susceptible <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of the designated organisms in the following diseases:</p>
<p><span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">Urinary tract infections</span> caused by <span class="Italics">E. coli, P. mirabilis, </span>and<span class="Italics"> Klebsiella</span> species.</p>
<p>Skin and skin structure <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> caused by staphylococci and/or streptococci.</p>
<p><span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">Pharyngitis</span> and/or <span class="product-label-link" type="condition" conceptid="4234533" conceptname="Tonsillitis">tonsillitis</span> caused by <span class="Italics">Streptococcus pyogenes</span> (Group A beta-hemolytic streptococci).</p>
<p><span class="Bold"><span class="Emphasis">Note:</span></span> Only penicillin by the intramuscular route of administration has been shown to be effective in the prophylaxis of <span class="product-label-link" type="condition" conceptid="442313" conceptname="Rheumatic fever">rheumatic fever</span>. DURICEF is generally effective in the eradication of streptococci from the oropharynx. However, data establishing the efficacy of DURICEF for the prophylaxis of subsequent <span class="product-label-link" type="condition" conceptid="442313" conceptname="Rheumatic fever">rheumatic fever</span> are not available.</p>
<p><span class="Bold"><span class="Emphasis">Note:</span></span> Culture and susceptibility tests should be initiated prior to and during therapy. Renal function studies should be performed when indicated.</p>
<p>To reduce the development of drug-resistant bacteria and maintain the effectiveness of DURICEF and other antibacterial drugs, DURICEF should be used only to treat or prevent <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="i4i_contraindications_ID_1B94A15F-3F14-447C-9474-13817BD289EB"></a><a name="section-6"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First">DURICEF is contraindicated in patients with known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergy</span> to the cephalosporin group of antibiotics.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="i4i_warnings_ID_E1A6E76B-ED2D-47B0-B367-5CC4ACBA7108"></a><a name="section-7"></a><p></p>
<h1>WARNINGS</h1>
<p class="First">BEFORE THERAPY WITH DURICEF IS INSTITUTED, CAREFUL INQUIRY SHOULD BE MADE TO DETERMINE WHETHER THE PATIENT HAS HAD PREVIOUS <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">HYPERSENSITIVITY REACTIONS</span> TO CEFADROXIL, CEPHALOSPORINS, PENICILLINS, OR OTHER DRUGS. IF THIS PRODUCT IS TO BE GIVEN TO PENICILLIN-SENSITIVE PATIENTS, CAUTION SHOULD BE EXERCISED BECAUSE CROSS-SENSITIVITY AMONG BETA-LACTAM ANTIBIOTICS HAS BEEN CLEARLY DOCUMENTED AND MAY OCCUR IN UP TO 10% OF PATIENTS WITH A HISTORY OF <span class="product-label-link" type="condition" conceptid="439224" conceptname="Drug allergy">PENICILLIN ALLERGY</span>.</p>
<p>IF AN <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">ALLERGIC REACTION</span> TO DURICEF OCCURS, DISCONTINUE THE DRUG. SERIOUS ACUTE <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">HYPERSENSITIVITY REACTIONS</span> MAY REQUIRE TREATMENT WITH EPINEPHRINE AND OTHER EMERGENCY MEASURES, INCLUDING OXYGEN, INTRAVENOUS FLUIDS, INTRAVENOUS ANTIHISTAMINES, CORTICOSTEROIDS, PRESSOR AMINES, AND AIRWAY MANAGEMENT, AS CLINICALLY INDICATED.</p>
<p><span class="Italics">Clostridium difficile</span> associated <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> (CDAD) has been reported with use of nearly all antibacterial agents, including DURICEF, and may range in severity from mild <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> to fatal <span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">colitis</span>. Treatment with antibacterial agents alters the normal flora of the colon leading to overgrowth of <span class="Italics">C. difficile</span>.</p>
<p><span class="Italics">C. difficile</span> produces toxins A and B which contribute to the development of CDAD. Hypertoxin producing <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of <span class="Italics">C. difficile</span> cause increased morbidity and mortality, as these <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> can be refractory to antimicrobial therapy and may require colectomy. CDAD must be considered in all patients who present with <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> following antibiotic use. Careful medical history is necessary since CDAD has been reported to occur over two months after the administration of antibacterial agents.</p>
<p>If CDAD is suspected or confirmed, ongoing antibiotic use not directed against <span class="Italics">C. difficile</span> may need to be discontinued. Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of <span class="Italics">C. difficile</span>, and surgical evaluation should be instituted as clinically indicated.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="i4i_precautions_ID_E0B7EED5-D2C4-4A37-B65B-BB9BD33E5E87"></a><a name="section-8"></a><p></p>
<h1>PRECAUTIONS</h1>
<div class="Section" data-sectionCode="34072-9">
<a name="i4i_precautions_general_ID_32DD3604-3628-464E-8E56-0D3E8A47F044"></a><a name="section-8.1"></a><p></p>
<h2>General</h2>
<p class="First">DURICEF should be used with caution in the presence of markedly <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span> (creatinine clearance rate of less than 50 mL/min/1.73 M<span class="Sup">2</span>). (See <a href="#i4i_dosage_admin_ID_E06C07A3-16EB-42B5-94D3-7388D1F853FF">DOSAGE AND ADMINISTRATION</a>.) In patients with known or suspected <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>, careful clinical observation and appropriate laboratory studies should be made prior to and during therapy.</p>
<p>Prescribing DURICEF in the absence of a proven or strongly suspected <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">bacterial infection</span> or a <span class="product-label-link" type="condition" conceptid="4118659" conceptname="Prophylactic">prophylactic</span> indication is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria.</p>
<p>Prolonged use of DURICEF may result in the overgrowth of nonsusceptible organisms. Careful observation of the patient is essential. If <span class="product-label-link" type="condition" conceptid="4105019" conceptname="Superimposed infection">superinfection</span> occurs during therapy, appropriate measures should be taken.</p>
<p>DURICEF should be prescribed with caution in individuals with history of gastrointestinal disease particularly <span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">colitis</span>.</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="i4i_info_patients_ID_5B5673EB-AE4F-4862-8295-B58D07F21B5B"></a><a name="section-8.2"></a><p></p>
<h2>Information for Patients</h2>
<p class="First">Patients should be counseled that antibacterial drugs including DURICEF should only be used to treat <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">bacterial infections</span>. They do not treat <span class="product-label-link" type="condition" conceptid="440029" conceptname="Viral disease">viral infections</span> (e.g., the <span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">common cold</span>). When DURICEF is prescribed to treat a <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">bacterial infection</span>, patients should be told that although it is common to feel better early in the course of therapy, the medication should be taken exactly as directed. Skipping doses or not completing the full course of therapy may (1) decrease the effectiveness of the immediate treatment and (2) increase the likelihood that bacteria will develop resistance and will not be treatable by DURICEF or other antibacterial drugs in the future.</p>
<p><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span> is a common problem caused by antibiotics which usually ends when the antibiotic is discontinued. Sometimes after starting treatment with antibiotics, patients can develop watery and <span class="product-label-link" type="condition" conceptid="443530" conceptname="Hematochezia">bloody stools</span> (with or without <span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">stomach cramps</span> and <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>) even as late as two or more months after having taken the last dose of the antibiotic. If this occurs, patients should contact their physician as soon as possible.</p>
</div>
<div class="Section" data-sectionCode="34074-5">
<a name="i4i_drug_lab_interaction_ID_F74F7662-B7E9-44AC-A0F6-173F0B4CC9F3"></a><a name="section-8.3"></a><p></p>
<h2>Drug/Laboratory Test Interactions</h2>
<p class="First">Positive direct Coombsâ€™ tests have been reported during treatment with the cephalosporin antibiotics. In hematologic studies or in transfusion cross-matching procedures when antiglobulin tests are performed on the minor side or in Coombsâ€™ testing of newborns whose mothers have received cephalosporin antibiotics before parturition, it should be recognized that a positive Coombsâ€™ test may be due to the drug.</p>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="i4i_carcinogenesis_mutagenesis_fertility_ID_657F4515-93A9-4CC2-8095-5A3796E7E729"></a><a name="section-8.4"></a><p></p>
<h2>Carcinogenesis, Mutagenesis and Impairment of Fertility</h2>
<p class="First">No long-term studies have been performed to determine carcinogenic potential. No genetic toxicity tests have been performed.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_pregnancy_B_ID_12D93C77-1D21-46CF-AD45-9BFAC1945F86"></a><a name="section-8.5"></a><p></p>
<h2>Pregnancy: Pregnancy Category B</h2>
<p class="First">Reproduction studies have been performed in mice and rats at doses up to 11 times the human dose and have revealed no evidence of impaired fertility or harm to the fetus due to cefadroxil monohydrate. There are, however, no adequate and well controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.</p>
</div>
<div class="Section" data-sectionCode="34079-4">
<a name="i4i_labour_delivery_ID_33372996-392B-4439-946B-8C023FF07F1E"></a><a name="section-8.6"></a><p></p>
<h2>Labor and Delivery</h2>
<p class="First">DURICEF has not been studied for use during labor and delivery. Treatment should only be given if clearly needed.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="i4i_nursing_mothers_ID_11C41F18-3DCE-40BB-BDCE-94141B506834"></a><a name="section-8.7"></a><p></p>
<h2>Nursing Mothers</h2>
<p class="First">Caution should be exercised when cefadroxil monohydrate is administered to a nursing mother.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="i4i_pediatric_use_ID_E68729FA-BA14-4DEE-A054-85EB7AB1B23D"></a><a name="section-8.8"></a><p></p>
<h2>Pediatric Use</h2>
<p class="First">(See <span class="Bold"><span class="Emphasis"><a href="#i4i_dosage_admin_ID_E06C07A3-16EB-42B5-94D3-7388D1F853FF">DOSAGE AND ADMINISTRATION</a></span></span>.)</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="i4i_geriatric_use_ID_0EEE7748-934F-4AA9-BF8B-FECEEB6C1A52"></a><a name="section-8.9"></a><p></p>
<h2>Geriatric Use</h2>
<p class="First">Of approximately 650 patients who received cefadroxil for the treatment of <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">urinary tract infections</span> in three clinical trials, 28% were 60 years and older, while 16% were 70 years and older. Of approximately 1000 patients who received cefadroxil for the treatment of skin and skin structure <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> in 14 clinical trials, 12% were 60 years and older while 4% were 70 years and over. No overall differences in safety were observed between the elderly patients in these studies and younger patients. Clinical studies of cefadroxil for the treatment of <span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">pharyngitis</span> or <span class="product-label-link" type="condition" conceptid="4234533" conceptname="Tonsillitis">tonsillitis</span> did not include sufficient numbers of patients 65 years and older to determine whether they respond differently from younger patients. Other reported clinical experience with cefadroxil has not identified differences in responses between elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out.</p>
<p>Cefadroxil is substantially excreted by the kidney, and dosage adjustment is indicated for patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (see <span class="Bold"><span class="Emphasis"><a href="#i4i_dosage_admin_ID_E06C07A3-16EB-42B5-94D3-7388D1F853FF">DOSAGE AND ADMINISTRATION</a>: <a href="#i4i_section_ID_B885144F-8711-4A1D-A3AC-12C2249A3446"><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></a></span></span>). Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="i4i_adverse_effects_ID_D72571F0-0792-4010-A40E-C7F1E6E0C80B"></a><a name="section-9"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_61967CA9-88F7-4CCF-955A-6FE710F717C5"></a><a name="section-9.1"></a><p></p>
<h2>Gastrointestinal</h2>
<p class="First">Onset of <span class="product-label-link" type="condition" conceptid="4265457" conceptname="Pseudomembranous enterocolitis">pseudomembranous colitis</span> symptoms may occur during or after antibiotic treatment (see <a href="#i4i_warnings_ID_E1A6E76B-ED2D-47B0-B367-5CC4ACBA7108">WARNINGS</a>). <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">Dyspepsia</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> have been reported rarely. <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span> has also occurred.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_62CBC541-B483-4D5C-A760-50A763F50022"></a><a name="section-9.2"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span></h2>
<p class="First">Allergies (in the form of <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span>, and <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>) have been observed. These reactions usually subsided upon discontinuation of the drug. <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">Anaphylaxis</span> has also been reported.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_AB8DA06D-5F1D-4105-84D1-C3B22E228C17"></a><a name="section-9.3"></a><p></p>
<h2>Other</h2>
<p class="First">Other reactions have included hepatic dysfunction including <span class="product-label-link" type="condition" conceptid="4143915" conceptname="Cholestasis">cholestasis</span> and elevations in serum transaminase, <span class="product-label-link" type="condition" conceptid="4146239" conceptname="Pruritus of genital organs">genital pruritus</span>, genital <span class="product-label-link" type="condition" conceptid="433968" conceptname="Candidiasis">moniliasis</span>, <span class="product-label-link" type="condition" conceptid="4081648" conceptname="Acute vaginitis">vaginitis</span>, moderate transient <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>. <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">Agranulocytosis</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>, idiosyncratic <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic failure</span>, <span class="product-label-link" type="condition" conceptid="132702" conceptname="Erythema multiforme">erythema multiforme</span>, <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span>, <span class="product-label-link" type="condition" conceptid="432522" conceptname="Transfusion reaction due to serum protein reaction">serum sickness</span>, and <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgia</span> have been rarely reported.</p>
<p>In addition to the adverse reactions listed above which have been observed in patients treated with cefadroxil, the following adverse reactions and altered laboratory tests have been reported for cephalosporin-class antibiotics:</p>
<p><span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">Toxic epidermal necrolysis</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="4105019" conceptname="Superimposed infection">superinfection</span>, renal dysfunction, <span class="product-label-link" type="condition" conceptid="4126119" conceptname="Toxic nephropathy">toxic nephropathy</span>, <span class="product-label-link" type="condition" conceptid="137829" conceptname="Aplastic anemia">aplastic anemia</span>, <span class="product-label-link" type="condition" conceptid="435503" conceptname="Hemolytic anemia">hemolytic anemia</span>, <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span>, prolonged <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time, positive Coombsâ€™ test, increased BUN, increased creatinine, elevated alkaline phosphatase, elevated <span class="product-label-link" type="condition" conceptid="4094657" conceptname="Aspartate aminotransferase">aspartate aminotransferase</span> (AST), elevated <span class="product-label-link" type="condition" conceptid="4211515" conceptname="Alanine aminotransferase">alanine aminotransferase</span> (ALT), elevated bilirubin, elevated LDH, <span class="product-label-link" type="condition" conceptid="4302954" conceptname="Disorder characterized by eosinophilia">eosinophilia</span>, <span class="product-label-link" type="condition" conceptid="432881" conceptname="Pancytopenia">pancytopenia</span>, <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>.</p>
<p>Several cephalosporins have been implicated in triggering <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>, particularly in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>, when the dosage was not reduced (see <a href="#i4i_dosage_admin_ID_E06C07A3-16EB-42B5-94D3-7388D1F853FF">DOSAGE AND ADMINISTRATION</a> and <a href="#i4i_overdosage_ID_B3B36D63-CA19-4EE3-9DCC-308D4A2B23BD">OVERDOSAGE</a>). If <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> associated with drug therapy occur, the drug should be discontinued. Anticonvulsant therapy can be given if clinically indicated.</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="i4i_overdosage_ID_B3B36D63-CA19-4EE3-9DCC-308D4A2B23BD"></a><a name="section-10"></a><p></p>
<h1>OVERDOSAGE</h1>
<p class="First">A study of children under six years of age suggested that ingestion of less than 250 mg/kg of cephalosporins is not associated with significant outcomes. No action is required other than general support and observation. For amounts greater than 250 mg/kg, induce gastric emptying.</p>
<p>In five anuric patients, it was demonstrated that an average of 63% of a 1 g oral dose is extracted from the body during a 6â€“8 hour hemodialysis session.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="i4i_dosage_admin_ID_E06C07A3-16EB-42B5-94D3-7388D1F853FF"></a><a name="section-11"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First">DURICEF is acid-stable and may be administered orally without regard to meals. Administration with food may be helpful in diminishing potential gastrointestinal complaints occasionally associated with oral cephalosporin therapy.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_1EE89923-7F5D-4683-85C9-4BF3725768B1"></a><a name="section-11.1"></a><p></p>
<h2>Adults</h2>
<p class="First"><span class="Italics"><span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">Urinary Tract Infections</span>:</span> For uncomplicated lower <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">urinary tract infections</span> (i.e., <span class="product-label-link" type="condition" conceptid="195588" conceptname="Cystitis">cystitis</span>) the usual dosage is 1 or 2 g per day in a single (q.d.) or divided doses (b.i.d.).</p>
<p>For all other <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">urinary tract infections</span> the usual dosage is 2 g per day in divided doses (b.i.d.).</p>
<p><span class="Italics">Skin and Skin Structure <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span>:</span> For skin and skin structure <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> the usual dosage is 1 g per day in single (q.d.) or divided doses (b.i.d.).</p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">Pharyngitis</span> and <span class="product-label-link" type="condition" conceptid="4234533" conceptname="Tonsillitis">Tonsillitis</span>:</span> Treatment of group A beta-hemolytic <span class="product-label-link" type="condition" conceptid="28060" conceptname="Streptococcal sore throat">streptococcal pharyngitis</span> and tonsillitisâ€”1 g per day in single (q.d.) or divided doses (b.i.d.) for 10 days.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_F9865457-CF70-494F-B30D-D86F032C9C0C"></a><a name="section-11.2"></a><p></p>
<h2>Children</h2>
<p class="First">For <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">urinary tract infections</span>, the recommended daily dosage for children is 30 mg/kg/day in divided doses every 12 hours. For <span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">pharyngitis</span>, <span class="product-label-link" type="condition" conceptid="4234533" conceptname="Tonsillitis">tonsillitis</span>, and <span class="product-label-link" type="condition" conceptid="140480" conceptname="Impetigo">impetigo</span>, the recommended daily dosage for children is 30 mg/kg/day in a single dose or in equally divided doses every 12 hours. For other skin and skin structure <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>, the recommended daily dosage is 30 mg/kg/day in equally divided doses every 12 hours. In the treatment of beta-hemolytic <span class="product-label-link" type="condition" conceptid="437779" conceptname="Streptococcal infectious disease">streptococcal infections</span>, a therapeutic dosage of DURICEF should be administered for at least 10 days.</p>
<p>See chart for total daily dosage for children.</p>
<a name="ID_FF54838E-9F33-4AF1-B6A4-97D577971322"></a><table border="single" frame="box" width="284">
<caption><span>DAILY DOSAGE OF DURICEF<span class="Sup">Â®</span> SUSPENSION</span></caption>
<col width="21.479%">
<col width="19.014%">
<col width="31.338%">
<col width="28.169%">
<thead>
<tr class="First">
<td align="left" colspan="2" valign="top">CHILD'S WEIGHT</td>
<td align="left" valign="top"></td>
<td align="left" valign="top"></td>
</tr>
<tr class="Last">
<td align="center" colspan="2" valign="top"><span class="Bold"><span class="Emphasis">lbs           kg</span></span></td>
<td align="center" valign="top"><span class="Bold"><span class="Emphasis">260 mg/5 mL</span></span></td>
<td align="center" valign="top"><span class="Bold"><span class="Emphasis">500 mg/5 mL</span></span></td>
</tr>
</thead>
<tbody>
<tr class="First">
<td align="center" valign="top">10</td>
<td align="center" valign="top">4.5</td>
<td align="center" valign="top">Â½ tsp</td>
<td align="left" valign="top"></td>
</tr>
<tr>
<td align="center" valign="top">20</td>
<td align="center" valign="top">9.1</td>
<td align="center" valign="top">1 tsp</td>
<td align="left" valign="top"></td>
</tr>
<tr>
<td align="center" valign="top">30</td>
<td align="center" valign="top">13.6</td>
<td align="center" valign="top">1Â½ tsp</td>
<td align="left" valign="top"></td>
</tr>
<tr>
<td align="center" valign="top">40</td>
<td align="center" valign="top">18.2</td>
<td align="center" valign="top">2 tsp</td>
<td align="center" valign="top">1 tsp</td>
</tr>
<tr>
<td align="center" valign="top">50</td>
<td align="center" valign="top">22.7</td>
<td align="center" valign="top">2Â½ tsp</td>
<td align="center" valign="top">1Â¼ tsp</td>
</tr>
<tr>
<td align="center" valign="top">60</td>
<td align="center" valign="top">27.3</td>
<td align="center" valign="top">3 tsp</td>
<td align="center" valign="top">1Â½ tsp</td>
</tr>
<tr class="Last">
<td align="center" valign="top">
<p class="First">70 &amp;</p>above</td>
<td align="center" valign="bottom">31.8+</td>
<td align="center" valign="bottom">â€”</td>
<td align="center" valign="top">                                    2 tsp</td>
</tr>
</tbody>
</table>
<p>Â </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_B885144F-8711-4A1D-A3AC-12C2249A3446"></a><a name="section-11.3"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></h2>
<p class="First">In patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>, the dosage of cefadroxil monohydrate should be adjusted according to creatinine clearance rates to prevent drug accumulation. The following schedule is suggested. In adults, the initial dose is 1000 mg of DURICEF and the maintenance dose (based on the creatinine clearance rate [mL/min/1.73 M<span class="Sup">2</span>]) is 500 mg at the time intervals listed below.</p>
<a name="ID_AFBA48F7-A6F0-46C4-96A8-DE81F151983E"></a><table border="single" frame="box" width="307">
<col width="45.928%">
<col width="54.072%">
<thead><tr class="First Last">
<td align="center" valign="middle"><span class="Bold"><span class="Emphasis">Creatinine Clearances</span></span></td>
<td align="center" valign="middle"><span class="Bold"><span class="Emphasis">Dosage Interval</span></span></td>
</tr></thead>
<tbody>
<tr class="First">
<td align="center" valign="middle">0Â­10 mL/min</td>
<td align="center" valign="middle">36 hours</td>
</tr>
<tr>
<td align="center" valign="middle">10Â­25 mL/min</td>
<td align="center" valign="middle">24 hours</td>
</tr>
<tr class="Last">
<td align="center" valign="middle">25Â­50 mL/min</td>
<td align="center" valign="middle">12 hours</td>
</tr>
</tbody>
</table>
<p>Â </p>
<p>Patients with creatinine clearance rates over 50 mL/min may be treated as if they were patients having normal renal function.</p>
<a name="ID_954BED49-1E8D-4B68-8213-23366023AB7F"></a><table border="single" frame="hsides" width="309.999">
<caption><span>Reconstitution Directions for Oral Suspension</span></caption>
<col width="21.935%">
<col width="78.065%">
<tbody class="Headless">
<tr class="First">
<td align="left" valign="top">Bottle Size</td>
<td align="left" valign="top">Reconstitution Directions</td>
</tr>
<tr>
<td align="left" valign="top">100 mL</td>
<td align="left" valign="top">
<p class="First">Suspend in a total of 67 mL water.</p>
<p>Method: Tap bottle lightly to loosen powder.</p>
<p>Add 67 mL of water in two portions. </p>Shake well after each addition.</td>
</tr>
<tr>
<td align="left" valign="top">75 mL</td>
<td align="left" valign="top">
<p class="First">Suspend in a total of 51 mL water.</p>
<p>Method: Tap bottle lightly to loosen powder.</p>
<p>Add 51 mL of water in two portions. </p>Shake well after each addition.</td>
</tr>
<tr>
<td align="left" valign="top">50 mL</td>
<td align="left" valign="top">
<p class="First">Suspend in a total of 34 mL water.</p>
<p>Method: Tap bottle lightly to loosen powder.</p>
<p>Add 34 mL of water in two portions.</p>Shake well after each addition.</td>
</tr>
<tr class="Last"><td align="left" colspan="2" valign="top">
<p class="First">After reconstitution, store in refrigerator. Shake well before using. </p>Keep container tightly closed. Discard unused portion after 14 days.</td></tr>
</tbody>
</table>
<p>Â </p>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="i4i_how_supplied_ID_A217B1B0-A466-43E5-95FC-E64D3AD8AF28"></a><a name="section-12"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">DURICEF<span class="Sup">Â®</span> (cefadroxil monohydrate, USP) 500 mg Capsules: opaque, maroon and white hard gelatin capsules, imprinted with â€œPPPâ€™â€™ and â€œ784â€™â€™ on one end and with â€œDURICEFâ€™â€™ and â€œ500 mgâ€™â€™ on the other end.</p>
<p>Capsules are supplied as follows:</p>
<p><span class="Bold"><span class="Emphasis">N</span></span> 0430-0780-19     Bottle of 50</p>
<p>Store at controlled room temperature 15Â°â€“30Â° C (59Â°â€“86Â° F).</p>
<p>DURICEF<span class="Sup">Â®</span> 1 gram Tablets: white to off white, top bisected, oval shaped, imprinted with â€œPPPâ€™â€™ on one side of the bisect and â€œ785â€™â€™ on the other side of the bisect. Tablets are supplied as follows:</p>
<p><span class="Bold"><span class="Emphasis">N</span></span> 0430-0781-19     Bottle of 50</p>
<p>Store at controlled room temperature 15Â°â€“30Â° C (59Â°â€“86Â° F).</p>
<p>DURICEF<span class="Sup">Â®</span> for Oral Suspension is orange-pineapple flavored, and is supplied as follows:</p>
<p>250 mg/5 mL      <span class="Bold"><span class="Emphasis">N</span></span> 0430-2782-15Â      50 mL Bottle</p>
<p><span class="Bold"><span class="Emphasis">                           N </span></span>0430-2782-17     100 mL Bottle</p>
<p>500 mg/5 mL<span class="Bold"><span class="Emphasis">     N</span></span> 0430-2783-16Â      75 mL Bottle</p>
<p><span class="Bold"><span class="Emphasis">    N</span></span> 0430-2783-17     100 mL Bottle</p>
<p>Prior to reconstitution: Store at controlled room temperature 15Â°â€“30Â° C (59Â°â€“86Â° F).</p>
</div>
<div class="Section" data-sectionCode="34093-5">
<a name="i4i_references_ID_BC2B0343-8A27-40F9-B755-592E33397462"></a><a name="section-13"></a><p></p>
<h1>REFERENCES</h1>
<p class="First">1.Â National Committee for Clinical Laboratory Standards, Approved Standard, <span class="Italics">Performance Standards for Antimicrobial Disk Susceptibility Test</span>, 4th Edition, Vol. 10 (7): M2-A4, Villanova, PA, April, 1990.</p>
<p>2.Â National Committee for Clinical Laboratory Standards, Approved Standard: <span class="Italics">Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically</span>, 2nd Edition, Vol. 10 (8): M7-A2, Villanova, PA, April, 1990.</p>
<p>Manufactured by Bristol-Myers Squibb Co.</p>
<p>Princeton, NJ 08543 </p>
<p>For Warner Chilcott Company, Inc.</p>
<p>Fajardo, PR 00738</p>
<p>Marketed by Warner Chilcott, Inc.</p>
<p>Rockaway, NJ 07866</p>
<p>2782G073</p>
<p>Revised April 2007</p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>DURICEFÂ 		
					</strong><br><span class="contentTableReg">cefadroxil powder, for suspension</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0430-2782</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>cefadroxil</strong> (cefadroxil) </td>
<td class="formItem"></td>
<td class="formItem">250Â mg Â inÂ 5Â mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FDC Yellow No. 6</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>flavors (natural and artificial)</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>polysorbate 80</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>sodium benzoate</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>sucrose</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>xanthan gum</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0430-2782-15</td>
<td class="formItem">50 mL in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:0430-2782-17</td>
<td class="formItem">100 mL in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">3</th>
<td class="formItem">NDC:0430-2782-95</td>
<td class="formItem">10 mL in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>DURICEFÂ 		
					</strong><br><span class="contentTableReg">cefadroxil powder, for suspension</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0430-2783</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>cefadroxil</strong> (cefadroxil) </td>
<td class="formItem"></td>
<td class="formItem">500Â mg Â inÂ 5Â mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FDC Yellow No. 6</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>flavors (natural and artificial)</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>polysorbate 80</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>sodium benzoate</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>sucrose</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>xanthan gum</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0430-2783-16</td>
<td class="formItem">75 mL in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:0430-2783-17</td>
<td class="formItem">100 mL in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">3</th>
<td class="formItem">NDC:0430-2783-95</td>
<td class="formItem">10 mL in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>DURICEFÂ 		
					</strong><br><span class="contentTableReg">cefadroxil tablet</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0430-0781</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>cefadroxil</strong> (cefadroxil) </td>
<td class="formItem"></td>
<td class="formItem">1Â g</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>microcrystalline cellulose</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>hydroxypropyl methylcellulose</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>magnesium stearate</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>polyethylene glycol</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>polysorbate 80</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>simethicone emulsion</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>titanium dioxide</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">WHITE (WHITE) </td>
<td class="formLabel">Score</td>
<td class="formItem">2 pieces</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">OVAL (OVAL) </td>
<td class="formLabel">Size</td>
<td class="formItem">21mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">PPP;785</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">Â Â Â Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Coating</td>
<td class="formItem">false</td>
<td class="formLabel">Symbol</td>
<td class="formItem">false</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0430-0781-19</td>
<td class="formItem">50  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>DURICEFÂ 		
					</strong><br><span class="contentTableReg">cefadroxil capsule</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0430-0780</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>cefadroxil</strong> (cefadroxil) </td>
<td class="formItem"></td>
<td class="formItem">500Â mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>DC Red No. 28</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FDC Blue No. 1</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FDC Red No. 40</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>gelatin</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>magnesium stearate</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>titanium dioxide</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">WHITE (WHITE) ,Â RED (MAROON) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">CAPSULE (CAPSULE) </td>
<td class="formLabel">Size</td>
<td class="formItem">21mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">PPP;784;Duricef;500</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">Â Â Â Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Coating</td>
<td class="formItem">true</td>
<td class="formLabel">Symbol</td>
<td class="formItem">false</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0430-0780-19</td>
<td class="formItem">50  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler -Â </span>Warner Chilcott, Inc.</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 5/2007<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>72ECA4F9-1CD2-2EB4-668B-CE52CC96C3E1</div>
<div>Set id: 4AD759F3-72DD-412E-9500-055335CDA6CF</div>
<div>Version: 1</div>
<div>Effective Time: 20070503</div>
</div>
</div>Â <div class="DistributorName">Warner Chilcott, Inc.</div></p>
</body></html>
